This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B
by Zacks Equity Research
Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.
Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.
Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU
by Zacks Equity Research
Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.
COLL or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
New Strong Buy Stocks for March 3rd
by Zacks Equity Research
ACGL, ACLS, COLL, SAH, and TGH have been added to the Zacks Rank #1 (Strong Buy) List on March 3, 2022.
Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.
Can Collegium Pharmaceutical (COLL) Climb 30% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.9% in Collegium Pharmaceutical (COLL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
by Zacks Equity Research
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.
Collegium Pharmaceutical (COLL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -170.19% and 66.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies
by Zacks Equity Research
Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.
Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.
Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues
by Zacks Equity Research
Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.
Is a Beat Likely for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows
by Zacks Equity Research
Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More
by Zacks Equity Research
Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.
BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium
by Zacks Equity Research
Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.
Collegium Pharmaceutical (COLL) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -76.09% and -6.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 High Earnings Yield Picks That You Shouldn't Miss Out On
by Rimmi Singhi
Reap handsome rewards by investing in high earnings yield stocks including MT, MTH, SIMO, DFIN, IRWD, and COLL.
Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy
by Zacks Equity Research
Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -20.59% and -1.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.